ClinicalTrials.gg
RecruitingNCT06698887Updated Oct 1, 2026

A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea

An observational study in Multiple Myeloma, sponsored by Bristol-Myers Squibb. Recruiting at 5 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Bristol-Myers Squibb · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Multiple Myeloma by Bristol-Myers Squibb — 9 open to participants now, 18 under way, 6 of them phase 3. Multiple Myeloma · Bristol-Myers Squibb.

Planned enrollment
32nd of 35
15 · median 355
Started
2024
with 6 others
Observational
35 of 149
2 open now
Primary completion
2031-03
later than 16 of 17 live
Registered
147th of 149
by date

Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 32nd largest by planned enrollment of the 35 observational ones that give a count, is one of 7 that started in 2024, is one of 35 observational ones, reaches primary completion later than 16 of the 17 other live ones, and was the 147th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

9 of the 149 studies in Multiple Myeloma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Multiple Myeloma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to monitor the long-term safety of participants who received idecabtagene vicleucel treatment as part of the KarMMa-9 (CA089-1043) Phase 3 clinical trial.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants with newly diagnosed multiple myeloma (NDMM) who had a suboptimal response after autologous stem cell transplantation (ASCT) and who were treated with idecabtagene vicleucel in the KarMMa-9 (CA089-1043) Phase 3 clinical trial.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants ≥19 years of age
  • Korean participants with newly diagnosed multiple myeloma who had a suboptimal response after stem cell transplantation (ASCT) and who were treated with idecabtagene vicleucel (assigned to Arm A) in the KarMMa-9 trial (CA089-1043)
  • Participants must understand and voluntarily sign and form (ICF) for the Korea long-term follow-up surveillance study prior to any surveillance-related procedures being conducted

Exclusion criteria

Exclusion Criteria:

  • Participants who participate in KarMMa-9 trial (CA089-1043) but disagree with long-term follow-up surveillance in Korea
  • Participants who are not possible to treat with Ide-cel within 9 days post-completion of lymphodepleting chemotherapy (LDC), if delays occur. However, depending on the participants recovery status, whether idecabtagene vicleucel is administered or not, should be discussed with a medical monitor
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants receiving idecabtagene vicleucel

    Drug: Idecabtagene vicleucel

Interventions

06

What researchers measure

Primary outcomes

  1. Participant adverse events

    Time frame: Monthly from months 4-18, every 2 months from months 19-59, and annually from month year 5 to 15

  2. Number of participants with positive replication-competent lentivirus test results

    Time frame: At 4, 7, 13, and 25 months, and annually up to 15 years

  3. Persistent vector sequence monitoring

    Time frame: Months 7-18 and annually from years 5-15

Secondary outcomes

  1. Progression-free survival (PFS)

    Time frame: Monthly up to 18 months and every two months after month 19 up to 15 years

  2. Overall survival (OS)

    Time frame: Every 3 months up to month 60, annually thereafter up to 15 years

  3. Number of participants that achieve complete response or stringent complete response

    Time frame: At months 4-18, every 2 months from months 19-59, and annually from years 5-15

  4. Health-related quality of life (HRQoL) measured by the European Organization for Research and Treatment of Cancer core quality of life (EORTC QLQ-C30) questionnaire

    Time frame: At months 4-18, every 2 months from months 19-59, and annually from years 5-15

  5. Health-related quality of life (HRQoL) measured by the European Organization for Research and Treatment of Cancer assessment of quality of life of myeloma patients (EORTC QLQ-MY20) questionnaire

    Time frame: At months 4-18, every 2 months from months 19-59, and annually from years 5-15

  6. Health-related quality of life (HRQoL) measured by the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire

    Time frame: At months 4-18, every 2 months from months 19-59, and annually from years 5-15

07

Study locations

5 of 5 sites recruiting
  • Chonnam National University Hwasun Hospital
    Hwasun, Jeonranamdo 58128, South Korea
    Recruiting
    • Sung Hoon Jung, Site 0041 · Contact82613797623
  • Seoul National University Hospital
    Seoul, Seoul-teukbyeolsi [Seoul] 03080, South Korea
    Recruiting
    • SungSoo Yoon, Site 0039 · Contact82-2-2072-3079
  • Asan Medical Center
    Seoul, Seoul-teukbyeolsi [Seoul] 05505, South Korea
    Recruiting
    • Dok Hyun Yoon, Site 0040 · Contact82230105940
  • Samsung Medical Center
    Seoul, Seoul-teukbyeolsi [Seoul] 06351, South Korea
    Recruiting
    • Kihyun Kim, Site 0038 · Contact+821099333456
  • The Catholic Univ. of Korea Seoul St. Mary's Hospital
    Seoul, Seoul-teukbyeolsi [Seoul] 06591, South Korea
    Recruiting
    • Chang Ki Min, Site 0043 · Contact82-20-2258-6053
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Mar 2031, 78 months after the start.

Of 66 industry-sponsored observational studies under Multiple Myeloma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 70. This study's planned 78 months is above that.

Counting every sponsor, half of 239 studies reached it within 57 months; a quarter within 30 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Nov 21, 2024
StartActual
Sep 11, 2024
Primary completionEst.
Mar 27, 2031
CompletionEst.
Mar 27, 2031
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06698887
Responsible party
Sponsor
First posted
Nov 21, 2024
Start date
Sep 11, 2024
Primary completion
Mar 27, 2031 (estimated)
Completion
Mar 27, 2031 (estimated)
Last update
Oct 1, 2026

Study contacts

BMS Study Connect Contact Center www.BMSStudyConnect.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion